Compare Regeneron Pharmaceuticals Inc (REGN) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Xpeng Inc - ADR — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.01 (market cap $76.14B), while Xpeng Inc - ADR trades at $9.97 (market cap $9.16B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.3× Xpeng Inc - ADR's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Xpeng Inc - ADR for 80 Days on average.
| REGN | XPEV | |
|---|---|---|
Market Cap | $76.14B | $9.16B |
Volume | 500,239 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $28.07 |
52-Week Low | $557.73 | $9.25 |
Typical Hold Time | 107 Days | 80 Days |
Enterprise Value | $70.85B | $11.09B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
XPeng (XPEV) trades at $9.58, up 0.21% today, with a bearish technical signal despite oversold RSI readings. The company reported strong Q4 2025 earnings beat but missed Q1 and Q2 2026 expectations. Revenue grew to $76.72B in 2025, with net losses narrowing to -$1.14B. Recent news highlights XPeng's expansion into humanoid robotics and global vehicle launches, including the G9L SUV debut at the Paris Motor Show.
XPeng shows improving revenue growth and narrowing losses, but persistent unprofitability and high EV/EBITDA of 144.25 pose valuation concerns. Analyst consensus is bullish with a $17.55 price target, though execution risks in new robotics ventures and competitive EV market pressures remain key challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
